WO2010088518A2 - Modulateurs hétérocycliques du gpr119 pour le traitement de maladies - Google Patents

Modulateurs hétérocycliques du gpr119 pour le traitement de maladies Download PDF

Info

Publication number
WO2010088518A2
WO2010088518A2 PCT/US2010/022588 US2010022588W WO2010088518A2 WO 2010088518 A2 WO2010088518 A2 WO 2010088518A2 US 2010022588 W US2010022588 W US 2010022588W WO 2010088518 A2 WO2010088518 A2 WO 2010088518A2
Authority
WO
WIPO (PCT)
Prior art keywords
recited
compound
c1nc2
chosen
optionally substituted
Prior art date
Application number
PCT/US2010/022588
Other languages
English (en)
Other versions
WO2010088518A3 (fr
Inventor
Mehmet Kahraman
Nicholas D. Smith
Celine Bonnefous
Stewart A. Noble
Joseph E. Payne
Original Assignee
Kalypsys, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys, Inc. filed Critical Kalypsys, Inc.
Publication of WO2010088518A2 publication Critical patent/WO2010088518A2/fr
Publication of WO2010088518A3 publication Critical patent/WO2010088518A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • Obesity is a growing threat to the global health by virtue of its association with a cluster of diseases that include insulin resistance, glucose intolerance, dyslipidemia, and hypertension, collectively known as the metabolic syndrome or syndrome X. It is well documented that patients with metabolic syndrome have a higher risk for cardiovascular diseases such as coronary heart disease and stroke [Grundy S. M. et al. Circulation 112:e285-e290, 2005]. The treatment of obesity will require complex solutions, including increased public awareness to diminish food portions, improved food choices and increased physical activity. However, epidemiologic studies have shown that treating diabetes/insulin resistance in these patients can reduce the risk of cardiovascular diseases such as coronary artery disease.
  • GPRl 19 modulators described herein represent such an opportunity.
  • Current therapies for diabetes mellitus include: insulin; insulin secretagogues, such as sulphonylureas, which increase insulin secretion from pancreatic ⁇ -cells; glucose-lowering effectors, such as metformin which reduce glucose production from the liver; activators of the peroxisome proliferator- activated receptor- ⁇ (PPAR- ⁇ ), such as the thiazolidinediones, which enhances insulin action; GLP-I mimetics, such as exenatide (Byetta); and ⁇ -glucosidase inhibitors which interfere with gut glucose production.
  • insulin secretagogues such as sulphonylureas, which increase insulin secretion from pancreatic ⁇ -cells
  • glucose-lowering effectors such as metformin which reduce glucose production from the liver
  • activators of the peroxisome proliferator- activated receptor- ⁇ (PPAR- ⁇ ) such as the thiazolidinediones,
  • GIP and GLP-I are peptides, known as incretins, secreted from enteroendocrine K- and L-cells respectively in response to ingestion of nutrients, and have a wide variety of physiological effects that have been described in numerous publications over the past two decades. See, for example, Bojanowska, E. et al., Med. Sd. Monit., 2005, Aug 5 11(8): RA271-8; Perry, T. et al., Curr. Alzheimer Res., 2005, July 2(3): 377-85; and Meier, JJ. et al., Diabetes Metab. Res.
  • GIP and GLP-I are potent stimulators of the body's ability to produce insulin in response to elevated levels of blood sugar.
  • GLP-I glucose-lowering effects in addition to GLP-l's ability to stimulate glucose-dependent insulin secretion including, but not limited to, an inhibition of the release of the hormone glucagon following meals, a reduction in the rate at which nutrients are absorbed into the bloodstream, and a reduction of food intake.
  • treatments to increase GLP-I may be used for a variety of conditions and disorders including but not limited to metabolic disorders, gastrointestinal disorders, inflammatory diseases, psychosomatic, depressive, and neuropsychiatric disease including but not limited to diabetes mellitus (Type 1 and Type 2), metabolic syndrome, obesity, appetite control and satiety, weight loss, stress, inflammation, myocardial ischemia/reperfusion injury, Alzheimer's Disease, and other diseases of the central nervous system.
  • Type II diabetes patients display a decreased responsiveness to GIP but not GLP-I, with respect to its ability to stimulate insulin secretion.
  • the mechanism behind the decreased responsiveness to GIP remains unclear since Type II diabetics retain sensitivity to a bolus administration of GIP but not to a continuous infusion (Meier et al. 2004 Diabetes 53 S220-S224).
  • Moreover recent studies with a long-acting fatty-acid derivative of GIP showed beneficial effects on glucose homeostasis in ob/ob mice following 14 days of treatment (Irwin N. et al. (2006) J. Med. Chem. 49, 1047-1 054).
  • GLP- 1 receptor agonists have proven elusive, a feature that unfortunately is characteristic of Class B GPCRs. Meanwhile, the spectrum of signaling peptides affected by inhibition of DPP-IV remains unclear and could potentially extend significantly beyond GLP-I and GIP (8, 9). It is therefore worthwhile to search for therapeutic approaches which afford both the physiological selectivity of GLP-I signaling and the opportunity for orally active treatment modalities.
  • GPRl 19 was identified as a Class A, islet-enriched receptor which could potentially mediate the insulinotropic actions of lysophosphatidylcholine (LPC) observed in vitro (Soga T., et al, Biochem Biophys Res Commun, 2005, 326:744-751), but a later study suggested that oleoylethanolamide (OEA) was a more potent GPRl 19 agonist (Overton H. A., et al., Cell Metab, 2006, 3:167-175). Recently, a small molecule GPR119 agonist has been shown to enhance glucose-dependent insulin secretion and improve hyperglycemia in rodent models of diabetes (Chu Z.
  • GPRl 19 is expressed in human gastrointestinal regions and in human islets. Activation of GPRl 19 has been demonstrated to stimulate intracellular cAMP and lead to glucose-dependent GLP- 1 and insulin secretion. See, T. Soga et al., Biochemical and Biophysical Research Communications 326 (2005) 744-751, herein incorporated by reference with regard to a background understanding of GPRl 19.
  • GPRl 19 activation of GPRl 19 is very unlikely to induce hypoglycemia (Chu Z., et al. Endocrinology, 2007, 148:2601-2609) [011] Agonists to GPRl 19 may be of therapeutic value for diabetes and associated conditions, particularly Type II diabetes, obesity, glucose intolerance, insulin resistance, metabolic syndrome X, hyperlipidemia, hypercholesterolemia, and atherosclerosis.
  • a and D are each independently chosen from heteroaryl, aryl, cycloalkyl, and heterocycloalkyl;
  • B is a bicyclic heteroaryl, which may be optionally substituted
  • Q is chosen from C and N;
  • V is chosen from a bond, O, S, NR5, and (CR 6 R T ) 1 ; W is chosen from a bond, O, S, NRs, and (CRgRiO) 5 ; X is chosen from a bond, O, S, NRn, and (CR 12 R 13 X;
  • Y is chosen from a bond, O, S, NR 14 , and
  • Z is chosen from alkyl, heteroalkyl, haloalkyl, perhaloalkyl, -CO 2 R 1 7, - CO 2 NR 1 8R 19 , aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, any of which may be optionally substituted; m, n, p, q, r, s, t, and u are each independently an integer from 0 to 4; each R 1 , R 2 , R 3 , and R 4 is independently chosen from hydrogen, null, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, amido, amino, aryl, aryloxy, carbamate, carboxy, cyano, cycloalkyl, halogen, heteroalkyl, heteroaryl, heterocycloalkyl
  • R 6 , R7, R9, Rio, R12, Ri3, Ri5, and R] 6 are each independently chosen from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, any of which may be optionally substituted; or R 6 and R 7 , or R 9 and Rio, or R 12 and Ri 3 , or Ri 5 and Ri 6 are taken together to form oxo; and
  • Ri 7 , Ri 8 , and R 19 are each independently chosen from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, any of which may be optionally substituted.
  • Certain compounds disclosed herein may possess useful GPRl 19 modulating activity, and may be used in the treatment or prophylaxis of a disease or condition in which GPRl 19 plays an active role.
  • certain embodiments also provide pharmaceutical compositions comprising one or more compounds disclosed herein together with a pharmaceutically acceptable carrier, as well as methods of making and using the compounds and compositions.
  • Certain embodiments provide methods for modulating GPRl 19.
  • Other embodiments provide methods for treating a GPRl 19-mediated disorder in a patient in need of such treatment, comprising administering to said patient a therapeutically effective amount of a compound or composition as disclosed herein.
  • certain compounds disclosed herein for use in the manufacture of a medicament for the treatment of a disease or condition ameliorated by the modulation of GPRl 19 activity.
  • B is a bicyclic heteroaryl containing between two and four nitrogens.
  • one of said nitrogens occupies a bridge position between the two fused rings.
  • B has the formula:
  • Xi is chosen from CH, C(R 2O ) and N;
  • X 2 is chosen from CH, C(R 21 ) and N;
  • X 3 is chosen from CH, C(R 22 ) and N;
  • X 4 is chosen from CH, C(R 23 ) and N;
  • X 5 is chosen from CH, C(R 24 ) and N;
  • X 6 is chosen from CH, C(R 25 ) and N;
  • X 7 is chosen from CH, C(R 26 ) and N;
  • R 2 o, R 2 I, R 22 , R 2 3, R 24 , R 2 5, and R 26 are each independently chosen from halogen, hydroxy, cyano, lower alkyl, lower alkoxy, trifluoromethyl, trifluoromethoxy, lower cycloalkyl, lower cycloalkylalkyl, lower heterocycloalkyl, lower heterocycloalkylalkyl, phenyl, lower phenylalkyl, lower heteroaryl, and lower heteroarylalkyl, any of which may be optionally substituted with one or more substituents chosen from hydrogen, halogen, hydroxy, cyano, methyl, ethyl, methoxy, trifluoromethyl, and trifluoromethoxy; and the dashed lines in the ring comprising X 4 - X 7 represent additional bonds which may be present or absent.
  • R 2 o, R 2 i, R 22 , R 2 i, R 25 , and R 26 are all hydrogen.
  • X 4 is nitrogen.
  • X 7 is nitrogen.
  • X] is nitrogen.
  • X 6 is nitrogen.
  • X 3 is nitrogen.
  • X 1 , X 4 , and X 6 are each nitrogen; and X 2 , X 3 , X 5 , and X 7 are each CH. [025] In certain embodiments,
  • X 1 , X 4 , X 5 , and X 6 are each nitrogen; and X 2 , X3, and X7 are each CH.
  • X 1 , X 5 , and X 7 are each nitrogen; and X 2 , X 3 , X 4 , and X 6 are each CH.
  • X 1 , X 4 , and X 5 are each nitrogen; and X 2 , X 3 , Xe, and X 7 are each CH.
  • X 4 and X 6 are each nitrogen; and X 1 , X 2 , X 3 , X 5 , and X 7 are each CH.
  • X 4 , X 5 , and X 6 are each nitrogen; and X 1 , X 2 , X 3 , and X 7 are each CH.
  • X 2 , X 4 , and X 6 are each nitrogen; and X 1 , X 3 , X 5 , and X 7 are each CH.
  • X 3 , X 4 , and X 6 are each nitrogen; and X 1 , X 2 , X 5 , and X 7 are each CH.
  • X 1 , X 3 , X 4 , and X 6 are each nitrogen; and X 2 , X 5 , and X 7 are each CH.
  • X 1 , X 6 , and X 7 are each nitrogen; and X 2 , X 3 , X 4 , and X 5 are each CH.
  • X 1 , X 3 , X 6 , and X 7 are each nitrogen; and X 2 , X 4 , and X 5 are each CH.
  • X 3 and X 4 are each nitrogen; and X 1 , X 2 , X 5 , X 6 , and X 7 are each CH.
  • X 1 , X 3 , and X 7 are each nitrogen;
  • X 2 , X 4 , X 5 , and X 6 are each CH. [037] In certain embodiments,
  • X] and X 7 are each nitrogen;
  • X 2 , X 3 , X 4 , Xs, and X 6 are each CH. [038] In certain embodiments,
  • X 3 and X 7 are each nitrogen;
  • Xi, X 2 , X 4 , X 5 , and X 6 are each CH. [039] In certain embodiments,
  • X 2 , X 4 , X 5 , and X 6 are each nitrogen;
  • X 1 , X3, and X 7 are each CH. [040] In certain embodiments,
  • X 2 , X 4 , and X 5 are each nitrogen;
  • Xi, X 3 , X 6 , and X 7 are each CH. [041] In certain embodiments,
  • X 3 , X 4 , and X 5 are each nitrogen;
  • Xi, X 2 , X 6 , and X 7 are each CH.
  • X 4 and X 5 are each nitrogen;
  • Xi, X 2 , X 3 , X 6 , and X 7 are each CH. [043] In certain embodiments,
  • Xi, X 3 , X 4 , and X 5 are each nitrogen;
  • X 2 , X 6 , and X 7 are each CH.
  • X 3 , X 4 , X 5 , and X 6 are each nitrogen;
  • Xi, X 2 , and X 7 are each CH. [045] In certain embodiments,
  • X 2 , X 4 , X 5 , and X 6 are each nitrogen;
  • Xi, X 3 , and X 7 are each CH. [046] In certain embodiments,
  • Xi, X 2 , X 4 , and X 5 are each nitrogen;
  • X 3 , X 6 , and X 7 are each CH. [047] In certain embodiments,
  • X 1 , X 2 , X 4 , and X 6 are each nitrogen;
  • X 3 , X 5 and X 7 are each CH.
  • X 2 , X3, X 6 , and X7 are each nitrogen;
  • X 1 , X 4 and X 5 are each CH. [049] In certain embodiments,
  • X 2 , X3, X5, and X7 are each nitrogen;
  • X 1 , X 4 and X 6 are each CH. [050] In certain embodiments,
  • X 3 , X 6 , and X 7 are each nitrogen;
  • X 1 , X 2 , X 4 , and X 5 are each CH. [051] In certain embodiments ,
  • X 1 , X 5 , and X 7 are each nitrogen;
  • X 2 , X 3 , X 4 , and X 6 are each CH.
  • X 1 , X 3 , and X 4 are each nitrogen;
  • X 2 , X 5 , X 6 , and X 7 are each CH.
  • X 1 , X 6 , and X 7 are each nitrogen;
  • X 2 , X 3 , X 4 , and X 5 are each CH.
  • X 1 , X 3 , X 6 , and X 7 are each nitrogen;
  • X 2 , X 4 , and X 5 are each CH.
  • X 3 and X 4 are each nitrogen;
  • X 1 , X 2 , X 5 , X 6 , and X 7 are each CH.
  • X 1 , X 3 , and X 7 are each nitrogen;
  • X 2 , X 4 , X 5 , and X 6 are each CH. [057] In certain embodiments,
  • X 1 and X 7 are each nitrogen;
  • X 2 , X 3 , X 4 , X 5 , and X 6 are each CH. [058] In certain embodiments,
  • X 3 and X 7 are each nitrogen; and Xi, X 2 , X 4 , Xs, and X 6 are each CH.
  • B is chosen from
  • B is chosen from
  • A is chosen from aryl, cycloalkyl and heterocycloalkyl, any of which may be optionally substituted;
  • Z is chosen from heteroaryl, aryl, and -CO 2 NRi 8 Ri 9 , either of which may be optionally substituted; and
  • r, s, t, and u are each independently an integer from 0 to 2.
  • each R 1 , R 2 , R 3 , and R 4 is independently chosen from hydrogen, null, acyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, amido, amino, carboxyl, cyano, halogen, hydroxyl, heteroaryl, nitro, perhaloalkoxy, perhaloalkyl, sulfonyl and sulfonamide, any of which may be optionally substituted; or R 2 and R 3 together may form an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl; and each R 5 , Rg, Rn, and R] 4 are independently chosen from hydrogen, acyl, lower alkyl, lower alkenyl, and lower alkyny
  • X and Y are each independently a bond.
  • the compounds have structural Formula II:
  • B is a bicyclic heteroaryl, containing between two and four nitrogens;
  • D is chosen from heteroaryl and aryl;
  • Z is chosen from heteroaryl, aryl, and -CO 2 NR 1 8R 19 , which may be optionally substituted;
  • Q is chosen from C and N; V is chosen from a bond, O, S, NR 5, , and (CR 6 Rv) 1,
  • W is chosen from a bond, O, S, NRg, and (CRgRiO) 8 ; m, n, p, and v are each independently an integer from 0 to 4; r is an integer from 0 to 1; s is an integer from 0 to 2; each R 1 , R 2 , and R 3 is independently chosen from hydrogen, null, acyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, amido, amino, carboxyl, cyano, halogen, hydroxyl, heteroaryl, nitro, perhaloalkoxy, perhaloalkyl, sulfonyl and sulfonamide, any of which may be optionally substituted; or R 2 and R 3 together may form an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl;
  • R 5 and R 8 are independently chosen from hydrogen, acyl, lower alkyl, lower alkenyl, and lower alkynyl;
  • R 6 , R 7 , R 9 and R] 0 are each independently chosen from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, any of which may be optionally substituted; R 9 and Rio are taken together to form oxo; and
  • Rn is chosen from hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, amido, amino, aryl, aryloxy, carbamate, carboxy, cyano, cycloalkyl, halogen, heteroalkyl, heteroaryl, heterocycloalkyl, hydroxyl, nitro, perhaloalkoxy, perhaloalkyl, and sulfonamide, any of which may be optionally substituted.
  • Q is N; s is an integer from 0 to 1 ;
  • V is chosen from a bond, O, NR5, and (CR 6 R?),-; and R 5 is chosen from hydrogen and lower alkyl.
  • Z is heteroaryl, which may be optionally substituted.
  • Z is a six-membered heteroaryl, which may be optionally substituted.
  • Z is an optionally substituted six- membered heteroaryl containing between 1 and 2 nitrogens.
  • Z is pyrimidine, which may be optionally substituted.
  • V is chosen from O and NR 5 ; and W is a bond.
  • V is a bond
  • W is a bond
  • V is chosen from O and NR 5 ; W is (CR 9 Ri 0 ); and
  • R 9 and R] 0 are each independently chosen from hydrogen, lower alkyl, lower alkenyl, lower alkynyl, or R 9 and Rio are taken together to form oxo.
  • R 9 and R] 0 are each independently chosen from hydrogen, lower alkyl, lower alkenyl, lower alkynyl, or R 9 and Rio are taken together to form oxo.
  • A is chosen from aryl, cycloalkyl, and heterocycloalkyl
  • B is a bicyclic heteroaryl containing between two and four nitrogens
  • D is chosen from heteroaryl and aryl
  • Z is chosen from heteroaryl, aryl, and -CO 2 NR 1 8R 19 , which may be optionally substituted;
  • Q is chosen from C and N;
  • V is chosen from a bond, O, S, NR 5 , and (CR 6 Rv) 1, ;
  • Y is chosen from a bond, O, S, NR 14 , and (CRisRi6) u ; m, n, p, and q are each independently an integer from 0 to 4; r, s, and u are each independently an integer from 0 to 1; each R 1 , R 2 , R 3 and R 4 is independently chosen from hydrogen, null, acyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, amido, amino, carboxyl, cyano, halogen, hydroxyl, heteroaryl, nitro, perhaloalkoxy, perhaloalkyl, sulfonyl and sulfonamide, any of which may be optionally substituted; or R 2 and R 3 together may form an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl;
  • R 5 and R] 4 are each independently chosen from hydrogen, acyl, lower alkyl, lower alkenyl, and lower alkynyl;
  • R 6 , R7, R 9 , Rio, Ri5 and R] 6 are each independently chosen from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, any of which may be optionally substituted; or R 9 and Rio are taken together to form oxo.
  • Q is N.
  • Z is heteroaryl, which may be optionally substituted.
  • Z is a six-membered heteroaryl, which may be optionally substituted.
  • Z is an optionally substituted six- membered heteroaryl containing between 1 and 2 nitrogens.
  • Z is pyrimidine, which may be optionally substituted.
  • s is 1; and R 9 and Rio are each independently chosen from hydrogen, lower alkyl, lower alkenyl, lower alkynyl, any of which may be optionally substituted; or R 9 and Rio are taken together to form oxo.
  • Y is chosen from O, (CRisRi6) u , and NRi 4 .
  • V is chosen from O, (CR 6 R 7 ),-, and NR 5 .
  • V is a bond.
  • W is a bond; and D is aryl.
  • Z is heteroaryl, which may be optionally substituted.
  • Z is a six-membered heteroaryl, which may be optionally substituted.
  • Z is an optionally substituted six- membered heteroaryl containing between 1 and 2 nitrogens.
  • Z is pyrimidine, which may be optionally substituted.
  • A is cycloalkyl.
  • Y is O.
  • A is aryl.
  • A is phenyl.
  • Q is N.
  • A is heterocycloalkyl.
  • A is 4- membered, 5- membered, or 6-membered heterocycloalkyl.
  • V is a bond.
  • D is aryl.
  • B is aryl; and R 2 and R 3 together form an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
  • B is heteroaryl; and R 2 and R 3 together form an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocycloalkyl.
  • compounds have structural Formula IV:
  • a and D are each independently chosen from heteroaryl, aryl, cycloalkyl, and heterocycloalkyl;
  • B is a bicyclic heteroaryl containing between two and four nitrogens
  • Qi and Q 2 are each independently chosen from C and N;
  • Z is chosen from aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, any of which may be optionally substituted;
  • V is chosen from a bond, O, S, NR5, and (CR ⁇ R ⁇ X; W is chosen from a bond, O, S, NRs, and (CRgR 10 X; X is chosen from a bond, O, S, NRn, and (CR 12 R 13 X;
  • Y is chosen from a bond, O, S, NR 14 , and m, n, p, q, r, s, t, and u are each independently an integer from 0 to 4; each R 1 , R 2 , R 3 , and R 4 is independently chosen from hydrogen, null, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, amido, amino, aryl, aryloxy, carbamate, carboxy, cyano, cycloalkyl, halogen, heteroalkyl, heteroaryl, heterocycloalkyl, hydroxyl, nitro, perhaloalkoxy, perhaloalkyl, sulfonyl and sulfonamide, any of which may be optionally substituted; or R 2 and R 3 together may form an optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted heterocycloalky
  • R 6 , R7, R9, Rio, R12, Ri3, Ri5, and R] 6 are each independently chosen from hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, any of which may be optionally substituted; or R 6 and R 7 , or R 9 and R] 0 , or R] 2 and Ri 3 , or Ri 5 and Ri 6 are taken together to form oxo.
  • X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , and X 7 are independently chosen from CH, C, and N;
  • Q 2 is chosen from C, CH, and N;
  • Q 3 is chosen from CRi, CH, and N;
  • Z is chosen from hydrogen, optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and -CO 2 Ri 7 ;
  • W is chosen from O and NH; m and q are independently an integer from 0 to 4; each Ri and R 4 is independently chosen from hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, amido, amino, aryl, aryloxy, carbamate, carboxy, cyano, cycloalkyl, halogen, heteroalkyl, heteroaryl, heterocycloalkyl, hydroxyl, nitro, perhaloalkoxy, perhaloalkyl, sulfonyl and sulfonamide, any of which may be optionally substituted; and
  • Rn is chosen from alkyl, alkenyl, and alkynyl, any of which may be optionally substituted.
  • Z is chosen from optionally substituted heterocycloalkyl, optionally substituted heteroaryl, and -CO 2 R 17 .
  • X 1 , X 2 , X3, X 4 , X 5 , X 6 , and X 7 are N.
  • said optionally substituted groups are substituted with between 0 and 4 substituents each independently chosen from lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, phenyloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyester, lower carboxamido, cyano, hydrogen, halogen, hydroxy, amino, lower alkylamino, arylamino, amido, nitro, thiol, lower alkylthio, lower haloalkylthio, lower perhaloalkylthio, arylthi
  • Q 2 is chosen from C and CH.
  • each Rj and R 4 is independently chosen from hydrogen, lower acyl, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, lower alkoxyalkyl, lower amido, lower amino, cyano, lower cycloalkyl, lower heterocycloalkyl, phenyl, lower phenylalkyl, lower meteroaryl, halogen, lower heteroalkyl, hydroxyl, nitro, lower perhaloalkoxy, lower perhaloalkyl, lower sulfonyl, and lower sulfonamide, any of which may be optionally substituted.
  • m and q are independently an integer from 0 to 2_
  • each R] and R 4 is independently chosen from lower alkyl, lower alkoxy, cyano, halogen, hydroxyl, nitro, perfluoromethoxy, perfluoromethyl, lower sulfonyl, and lower sulfonamide.
  • m and q are independently an integer from 0 to
  • each R lower alkyl.
  • q is 0.
  • m is an integer from 1 to 2.
  • each R 4 is independently chosen from methyl, halogen, and methylsulfonyl.
  • Z is chosen from optionally substituted optionally substituted heteroaryl and -CO 2 R 1 7.
  • Z is lower heteroaryl, which may be optionally substituted.
  • Z is a six-membered heteroaryl, which may be optionally substituted.
  • Z is an optionally substituted six- membered heteroaryl containing between 1 and 2 nitrogens.
  • Z is chosen from pyrimidine and oxadiazole, either of which may be optionally substituted.
  • Q 3 is N.
  • Q 3 is CH.
  • R n is optionally substituted lower alkyl.
  • Rj 7 is lower alkyl.
  • Z is chosen from optionally substituted monocyclic heteroaryl and -CO 2 R 1 7.
  • X 1 , X 4 , and X 6 are each nitrogen;
  • X 2 , X 3 , X 5 , and X 7 are each CH.
  • X 1 , X 4 , X5, and X 6 are each nitrogen;
  • X 2 , X 3 , and X 7 are each CH.
  • X 1 , X 5 , and X 7 are each nitrogen;
  • X 2 , X 3 , X 4 , and X 6 are each CH. [0129] In certain embodiments ,
  • X 1 , X 4 , and X 5 are each nitrogen;
  • X 2 , X 3 , X 6 , and X 7 are each CH. [0130] In certain embodiments ,
  • X 4 and X 6 are each nitrogen; and Xi, X 2 , X 3 , Xs, and X 7 are each CH.
  • X 4 , X 5 , and X 6 are each nitrogen; and Xi, X 2 , X 3 , and X 7 are each CH.
  • X 2 , X 4 , and X 6 are each nitrogen; and Xi, X 3 , X 5 , and X 7 are each CH.
  • X 3 , X 4 , and X 6 are each nitrogen; and Xi, X 2 , X 5 , and X 7 are each CH.
  • Xi, X 3 , X 4 , and X 6 are each nitrogen; and X 2 , X 5 , and X 7 are each CH.
  • X 1 , X 6 , and X 7 are each nitrogen; and X 2 , X 3 , X 4 , and X 5 are each CH.
  • X 1 , X 3 , Xe, and X 7 are each nitrogen; and X 2 , X 4 , and X 5 are each CH.
  • X 3 and X 4 are each nitrogen; and Xi, X 2 , X 5 , X 6 , and X 7 are each CH.
  • X 1 , X 3 , and X 7 are each nitrogen; and X 2 , X 4 , X 5 , and X 6 are each CH.
  • Xi and X 7 are each nitrogen; and X 2 , X 3 , X 4 , X 5 , and X 6 are each CH.
  • X 3 and X 7 are each nitrogen; and Xi, X 2 , X 4 , X 5 , and X 6 are each CH.
  • X 2 , X 4 , X 5 , and X 6 are each nitrogen;
  • X 1 , X3, and X7 are each CH. [0142] In certain embodiments ,
  • X 2 , X 4 , and X 5 are each nitrogen;
  • Xi, X 3 , X 6 , and X 7 are each CH. [0143] In certain embodiments ,
  • X 3 , X 4 , and X 5 are each nitrogen;
  • Xi, X 2 , X 6 , and X 7 are each CH.
  • X 4 and X 5 are each nitrogen;
  • Xi, X 2 , X 3 , X 6 , and X 7 are each CH.
  • X 1 , X 3 , X 4 , and X5 are each nitrogen;
  • X 2 , X 6 , and X 7 are each CH.
  • X 3 , X 4 , X 5 , and X 6 are each nitrogen;
  • X 1 , X 2 , and X 7 are each CH. [0147] In certain embodiments ,
  • X 2 , X 4 , X 5 , and X 6 are each nitrogen;
  • Xi, X 3 , and X 7 are each CH.
  • X 1 , X 2 , X 4 , and X5 are each nitrogen;
  • X 3 , X 6 , and X 7 are each CH.
  • X 1 , X 2 , X 4 , and X 6 are each nitrogen;
  • X 3 , X 5 and X 7 are each CH.
  • X 2 , X 3 , X 6 , and X 7 are each nitrogen;
  • X 1 , X 4 and X 5 are each CH.
  • X 2 , X 3 , X 5 , and X 7 are each nitrogen;
  • X 1 , X 4 and X 6 are each CH. [0152] In certain embodiments ,
  • X 3 , X 6 , and X 7 are each nitrogen;
  • Xi, X 2 , X 4 , and X 5 are each CH.
  • Xi, X 5 , and X 7 are each nitrogen;
  • X 2 , X 3 , X 4 , and X 6 are each CH. [0154] In certain embodiments ,
  • Xi, X 3 , and X 4 are each nitrogen;
  • X 2 , X 5 , Xe, and X 7 are each CH.
  • Xi, X 6 , and X 7 are each nitrogen;
  • X 2 , X 3 , X 4 , and X 5 are each CH.
  • Xi, X 3 , X 6 , and X 7 are each nitrogen;
  • X 2 , X 4 , and X 5 are each CH.
  • X 3 and X 4 are each nitrogen;
  • Xi, X 2 , X 5 , X 6 , and X 7 are each CH.
  • Xi, X 3 , and X 7 are each nitrogen;
  • X 2 , X 4 , X 5 , and X 6 are each CH.
  • Xi and X 7 are each nitrogen;
  • X 2 , X 3 , X 4 , X 5 , and X 6 are each CH. [0160] In certain embodiments ,
  • X 3 and X 7 are each nitrogen;
  • Xi, X 2 , X 4 , X 5 , and X 6 are each CH.
  • composition comprising a compound as disclosed herein together with a pharmaceutically acceptable carrier.
  • pharmaceutical composition comprises a compound chosen from those recited in Examples 1 to 55 together with a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is useful for the treatment or prevention of a GPR119-mediated disease.
  • a method of modulating GPRl 19 comprising contacting GPRl 19 with a compound as disclosed herein.
  • Also provided herein is a method of treatment of a GPRl 19-mediated disease comprising the administration of a therapeutically effective amount of a compound as disclosed herein to a patient in need thereof.
  • said disease is a metabolic disease.
  • said disease is diabetes.
  • Also provided herein is a method of treatment of a GPRl 19-mediated disease comprising the administration of: a therapeutically effective amount of a compound as disclosed herein; and another therapeutic agent.
  • said agent is chosen from insulin, metformin, Glipizide, glyburide, Amaryl, gliclazide, meglitinides, nateglinide, repaglinide, pramlintide, PTP-112, SB-517955, SB-4195052, SB-216763, NN-57-05441, NN- 57-05445, GW-0791, AGN-194204, T-1095, BAY R3401, acarbose, miglitol, voglibose, Exendin-4, DPP728, LAF237, vildagliptin , BMS477118, PT-100, GSK-823093, PSN-9301, T-6666, SYR-322, SYR-619, Liraglutide, CJC-1134-PC, naliglutide, MK-0431, saxagliptin, GSK23A, pioglitazone,
  • Also provided herein is a method for achieving an effect in a patient comprising the administration of a therapeutically effective amount of a compound as disclosed herein to a patient, wherein the effect is GLP-I secretion, lowering of blood glucose, improve glucose tolerance, decrease in insulin resistance, improvement in glucose-stimulated insulin secretion, preservation or restoration of pancreatic ⁇ -cell function, increased antihyperglycemic efficacy, weight loss, lowering of triglycerides, lowering of LDL, increase of HDL, lowering of blood pressure, and inhibition of bone resorption.
  • said effect is improvement in glucose- stimulated insulin secretion without hypoglycemia.
  • acyl refers to a carbonyl attached to an alkenyl, alkyl, aryl, cycloalkyl, heteroaryl, heterocycle, or any other moiety were the atom attached to the carbonyl is carbon.
  • An “acetyl” group refers to a -C(O)CH 3 group.
  • An “alkylcarbonyl” or “alkanoyl” group refers to an alkyl group attached to the parent molecular moiety through a carbonyl group. Examples of such groups include methylcarbonyl and ethylcarbonyl. Examples of acyl groups include formyl, alkanoyl and aroyl.
  • alkenyl refers to a straight-chain or branched-chain hydrocarbon group having one or more double bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkenyl will comprise from 2 to 6 carbon atoms.
  • alkoxy refers to an alkyl ether group, wherein the term alkyl is as defined below.
  • suitable alkyl ether groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso- butoxy, sec-butoxy, tert-butoxy, and the like.
  • alkyl refers to a straight-chain or branched-chain alkyl group containing from 1 to 20 carbon atoms.
  • said alkyl will comprise from 1 to 10 carbon atoms. In further embodiments, said alkyl will comprise from 1 to 6 carbon atoms.
  • Alkyl groups may be optionally substituted as defined herein. Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec -butyl, tert-butyl, pentyl, iso-amyl, hexyl, octyl, noyl and the like.
  • alkylene refers to a saturated aliphatic group derived from a straight or branched chain saturated hydrocarbon attached at two or more positions, such as methylene (-CH 2 -). Unless otherwise specified, the term “alkyl” may include “alkylene” groups.
  • alkylamino refers to an alkyl group attached to the parent molecular moiety through an amino group.
  • Suitable alkylamino groups may be mono- or dialkylated, forming groups such as, for example, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N- ethylmethylamino and the like.
  • alkylidene refers to an alkenyl group in which one carbon atom of the carbon-carbon double bond belongs to the moiety to which the alkenyl group is attached.
  • alkylthio refers to an alkyl thioether (R-S-) group wherein the term alkyl is as defined above and wherein the sulfur may be singly or doubly oxidized.
  • suitable alkyl thioether groups include methylthio, ethylthio, n-propylthio, isopropylthio, n- butylthio, iso-butylthio, sec-butylthio, tert-butylthio, methanesulfonyl, ethanesulfinyl, and the like.
  • alkynyl refers to a straight-chain or branched chain hydrocarbon group having one or more triple bonds and containing from 2 to 20 carbon atoms. In certain embodiments, said alkynyl comprises from 2 to 6 carbon atoms. In further embodiments, said alkynyl comprises from 2 to 4 carbon atoms.
  • alkynylene refers to a carbon- carbon triple bond attached at two positions such as ethynylene (-C:::C-, -C ⁇ C-).
  • alkynyl groups examples include ethynyl, propynyl, hydroxypropynyl, butyn-1- yl, butyn-2-yl, pentyn-1-yl, 3-methylbutyn-l-yl, hexyn-2-yl, and the like.
  • alkynyl may include “alkynylene” groups.
  • acylamino as used herein, alone or in combination, embraces an acyl group attached to the parent moiety through an amino group.
  • An example of an “acylamino” group is acetylamino (CH 3 C(O)NH-).
  • amino refers to — NRR , wherein R and R are independently chosen from hydrogen, alkyl, acyl, heteroalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, any of which may themselves be optionally substituted. Additionally, R and R' may combine to form heterocycloalkyl, either of which may be optionally substituted.
  • aryl as used herein, alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such polycyclic ring systems are fused together.
  • aryl embraces aromatic groups such as phenyl, naphthyl, anthracenyl, and phenanthryl.
  • arylalkenyl or “aralkenyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkenyl group.
  • arylalkoxy or “aralkoxy,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkoxy group.
  • arylalkyl or “aralkyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkyl group.
  • arylalkynyl or “aralkynyl,” as used herein, alone or in combination, refers to an aryl group attached to the parent molecular moiety through an alkynyl group.
  • arylalkanoyl or “aralkanoyl” or “aroyl,”as used herein, alone or in combination, refers to an acyl group derived from an aryl-substituted alkanecarboxylic acid such as benzoyl, napthoyl, phenylacetyl, 3-phenylpropionyl
  • hydrocinnamoyl 4-phenylbutyryl, (2-naphthyl)acetyl, 4-chlorohydrocinnamoyl, and the like.
  • aryloxy refers to an aryl group attached to the parent molecular moiety through an oxy.
  • carbamate refers to an ester of carbamic acid (-NHCOO-) which may be attached to the parent molecular moiety from either the nitrogen or acid end, and which may be optionally substituted as defined herein.
  • O-carbamyl refers to a -OC(O)NRR', group-with R and R' as defined herein.
  • N-carbamyl as used herein, alone or in combination, refers to a ROC(O)NR'- group, with R and R' as defined herein.
  • carboxyl or “carboxy,” as used herein, refers to -C(O)OH or the corresponding “carboxylate” anion, such as is in a carboxylic acid salt.
  • O-carboxy group refers to a RC(O)O- group, where R is as defined herein.
  • C-carboxy group refers to a -C(O)OR groups where R is as defined herein.
  • cycloalkyl or, alternatively, “carbocycle,” as used herein, alone or in combination, refers to a saturated or partially saturated monocyclic, bicyclic or tricyclic alkyl group wherein each cyclic moiety contains from 3 to 12 carbon atom ring members and which may optionally be a benzo fused ring system which is optionally substituted as defined herein.
  • said cycloalkyl will comprise from 5 to 7 carbon atoms.
  • cycloalkyl groups examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, tetrahydronapthyl, indanyl, octahydronaphthyl, 2,3-dihydro-lH-indenyl, adamantyl and the like.
  • "Bicyclic” and "tricyclic” as used herein are intended to include both fused ring systems, such as decahydronaphthalene, octahydronaphthalene as well as the multicyclic (multicentered) saturated or partially unsaturated type. The latter type of isomer is exemplified in general by, bicyclo[l,l,l]pentane, camphor, adamantane, and bicyclo[3,2,l]octane.
  • ester refers to a carboxy group bridging two moieties linked at carbon atoms.
  • ether refers to an oxy group bridging two moieties linked at carbon atoms.
  • halogen or halo
  • fluorine chlorine, bromine, or iodine
  • haloalkoxy refers to a haloalkyl group attached to the parent molecular moiety through an oxygen atom.
  • haloalkyl refers to an alkyl group having the meaning as defined above wherein one or more hydrogens are replaced with a halogen. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl groups. A monohaloalkyl group, for one example, may have an iodo, bromo, chloro or fluoro atom within the group.
  • Dihalo and polyhaloalkyl groups may have two or more of the same halo atoms or a combination of different halo groups.
  • haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
  • "Haloalkylene" refers to a haloalkyl group attached at two or more positions. Examples include fluoromethylene
  • heteroalkyl refers to a stable straight or branched chain, or cyclic hydrocarbon group, or combinations thereof, fully saturated or containing from 1 to 3 degrees of unsaturation, consisting of the stated number of carbon atoms and from one to three heteroatoms chosen from O, N, and S, and wherein the nitrogen and sulfur atoms may optionally be oxidized and the nitrogen heteroatom may optionally be quaternized.
  • the heteroatom(s) O, N and S may be placed at any interior position of the heteroalkyl group. Up to two heteroatoms may be consecutive, such as, for example, -CH 2 -NH- OCH 3 .
  • heteroaryl refers to a 3 to 7 membered unsaturated heteromonocyclic ring, or a fused monocyclic, bicyclic, or tricyclic ring system in which at least one of the fused rings is aromatic, which contains at least one atom chosen from O, S, and N.
  • said heteroaryl will comprise from 5 to 7 carbon atoms.
  • heterocyclic rings are fused with aryl rings, wherein heteroaryl rings are fused with other heteroaryl rings, wherein heteroaryl rings are fused with heterocycloalkyl rings, or wherein heteroaryl rings are fused with cycloalkyl rings.
  • heteroaryl groups include pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, pyranyl, furyl, thienyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, thiadiazolyl, isothiazolyl, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, indazolyl, benzotriazolyl, benzodioxolyl, benzopyranyl, benzoxazolyl, benzoxadiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, benzothienyl, chromonyl,
  • Exemplary tricyclic heterocyclic groups include carbazolyl, benzidolyl, phenanthrolinyl, dibenzofuranyl, acridinyl, phenanthridinyl, xanthenyl and the like.
  • heterocycloalkyl and, interchangeably, “heterocycle,” as used herein, alone or in combination, each refer to a saturated, partially unsaturated, or fully unsaturated monocyclic, bicyclic, or tricyclic heterocyclic group containing at least one heteroatom as a ring member, wherein each said heteroatom may be independently chosen from nitrogen, oxygen, and sulfur
  • said hetercycloalkyl will comprise from 1 to 4 heteroatoms as ring members.
  • said hetercycloalkyl will comprise from 1 to 2 heteroatoms as ring members.
  • said hetercycloalkyl will comprise from 3 to 8 ring members in each ring.
  • said hetercycloalkyl will comprise from 3 to 7 ring members in each ring. In yet further embodiments, said hetercycloalkyl will comprise from 5 to 6 ring members in each ring.
  • "Heterocycloalkyl" and “heterocycle” are intended to include sulfones, sulfoxides,
  • heterocycle groups include aziridinyl, azetidinyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinolinyl, dihydrocinnolinyl, dihydrobenzodioxinyl, dihydro[l,3]oxazolo[4,5-b]pyridinyl, benzo thiazolyl, dihydroindolyl, dihy- dropyridinyl, 1,3-dioxanyl, 1 ,4-dioxanyl, 1,3-dioxolanyl, isoindolinyl, morpholinyl, piperazinyl, pyrrolidinyl, tetrahydropyridinyl, piperidinyl, thiomorpholinyl, and the like.
  • the heterocycle groups may be optionally substituted unless specifically prohibited.
  • hydrazinyl as used herein, alone or in combination, refers to two amino groups joined by a single bond, i.e., -N-N-.
  • hydroxyalkyl refers to a hydroxy group attached to the parent molecular moiety through an alkyl group.
  • isocyanato refers to a -NCO group.
  • isothiocyanato refers to a -NCS group.
  • linear chain of atoms refers to the longest straight chain of atoms independently chosen from carbon, nitrogen, oxygen and sulfur.
  • lower aryl as used herein, alone or in combination, means phenyl or naphthyl, which may be optionally substituted as provided.
  • lower heteroaryl means either 1) monocyclic heteroaryl comprising five or six ring members, of which between one and four said members may be heteroatoms chosen from O, S, and N, or 2) bicyclic heteroaryl, wherein each of the fused rings comprises five or six ring members, comprising between them one to four heteroatoms chosen from
  • lower cycloalkyl as used herein, alone or in combination, means a monocyclic cycloalkyl having between three and six ring members. Lower cycloalkyls may be unsaturated. Examples of lower cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • lower heterocycloalkyl as used herein, alone or in combination, means a monocyclic heterocycloalkyl having between three and six ring members, of which between one and four may be heteroatoms chosen from O,
  • lower heterocycloalkyls include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, piperidinyl, piperazinyl, and morpholinyl.
  • Lower heterocycloalkyls may be unsaturated.
  • lower amino refers to — NRR , wherein R and R are independently chosen from hydrogen, lower alkyl, and lower heteroalkyl, any of which may be optionally substituted. Additionally, the R and R' of a lower amino group may combine to form a five- or six-membered heterocycloalkyl, either of which may be optionally substituted.
  • mercaptyl as used herein, alone or in combination, refers to an RS- group, where R is as defined herein.
  • perhaloalkoxy refers to an alkoxy group where all of the hydrogen atoms are replaced by halogen atoms.
  • perhaloalkyl refers to an alkyl group where all of the hydrogen atoms are replaced by halogen atoms.
  • sulfonate refers the -SO 3 H group and its anion as the sulfonic acid is used in salt formation.
  • sulfanyl refers to -
  • thia and thio refer to a -S- group or an ether wherein the oxygen is replaced with sulfur.
  • the oxidized derivatives of the thio group namely sulfinyl and sulfonyl, are included in the definition of thia and thio.
  • N-thiocarbamyl refers to an ROC(S)NR'- group, with R and
  • O-thiocarbamyl refers to a -OC(S)NRR' , group with R and
  • thiocyanato refers to a -CNS group.
  • trihalomethanesulfonamido refers to a X 3 CS(O) 2 NR- group with X is a halogen and R as defined herein.
  • trihalomethanesulfonyl refers to a X 3 CS(O) 2 - group
  • X is a halogen
  • trihalomethoxy refers to a X 3 CO- group where X is a halogen.
  • trimethysilyl as used herein, alone or in combination, refers to a silicone group substituted at its three free valences with groups as listed herein under the definition of substituted amino. Examples include trimethysilyl, tert-butyldimethylsilyl, triphenylsilyl and the like.
  • Any definition herein may be used in combination with any other definition to describe a composite structural group. By convention, the trailing element of any such definition is that which attaches to the parent moiety.
  • the composite group alkylamido would represent an alkyl group attached to the parent molecule through an amido group
  • the term alkoxy alkyl would represent an alkoxy group attached to the parent molecule through an alkyl group.
  • the term "optionally substituted” means the anteceding group may be substituted or unsubstituted.
  • the substituents of an "optionally substituted” group may include, without limitation, one or more substituents independently chosen from the following groups or a particular designated set of groups, alone or in combination: lower alkyl, lower alkenyl, lower alkynyl, lower alkanoyl, lower heteroalkyl, lower heterocycloalkyl, lower haloalkyl, lower haloalkenyl, lower haloalkynyl, lower perhaloalkyl, lower perhaloalkoxy, lower cycloalkyl, phenyl, aryl, aryloxy, lower alkoxy, lower haloalkoxy, oxo, lower acyloxy, carbonyl, carboxyl, lower alkylcarbonyl, lower carboxyester, lower carboxamido, cyano, hydrogen, halogen, hydroxy, amino, lower alkylcarbonyl
  • Two substituents may be joined together to form a fused five-, six-, or seven-membered carbocyclic or heterocyclic ring consisting of zero to three heteroatoms, for example forming methylenedioxy or ethylenedioxy.
  • An optionally substituted group may be unsubstituted (e.g., -CH 2 CH 3 ), fully substituted (e.g., - CF 2 CF 3 ), monosubstituted (e.g., -CH 2 CH 2 F) or substituted at a level anywhere in- between fully substituted and monosubstituted (e.g., -CH 2 CF 3 ).
  • R or the term R' appearing by itself and without a number designation, unless otherwise defined, refers to a moiety chosen from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which may be optionally substituted.
  • Asymmetric centers exist in the compounds disclosed herein. These centers are designated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom. It should be understood that the invention encompasses all stereochemical isomeric forms, including diastereomeric, enantiomeric, and epimeric forms, as well as d-isomers and 1-isomers, and mixtures thereof.
  • Individual stereoisomers of compounds can be prepared synthetically from commercially available starting materials which contain chiral centers or by preparation of mixtures of enantiomeric products followed by separation such as conversion to a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on chiral chromatographic columns, or any other appropriate method known in the art.
  • Starting compounds of particular stereochemistry are either commercially available or can be made and resolved by techniques known in the art.
  • the compounds disclosed herein may exist as geometric isomers.
  • the present invention includes all cis, trans, syn, anti,
  • bonds refers to a covalent linkage between two atoms, or two moieties when the atoms joined by the bond are considered to be part of larger substructure. A bond may be single, double, or triple unless otherwise specified. A dashed line between two atoms in a drawing of a molecule indicates that an additional bond may be present or absent at that position.
  • disease as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.
  • combination therapy means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
  • GPRl 19 modulator is used herein to refer to a compound that exhibits an EC 50 with respect to GPRl 19 activity of no more than about 100 ⁇ M and more typically not more than about 50 ⁇ M, as measured in the cAMP production assay and glucagon- like peptide- 1 (GLP-I) secretion assays described generally hereinbelow.
  • EC 50 is that concentration of inhibitor which activates the activity of an enzyme (e.g., GPRl 19) to half-maximal level. Certain compounds disclosed herein have been discovered to exhibit modulatory activity against GPRl 19.
  • compounds will exhibit an EC 50 with respect to GPRl 19 of no more than about 10 ⁇ M; in further embodiments, compounds will exhibit an EC 50 with respect to GPRl 19 of no more than about 5 ⁇ M; in yet further embodiments, compounds will exhibit an EC 50 with respect to GPRl 19 of not more than about 1 ⁇ M; in yet further embodiments, compounds will exhibit an EC 50 with respect to GPRl 19 of not more than about 200 nM, as measured in the GPRl 19 assay described herein.
  • the phrase "therapeutically effective” is intended to qualify the amount of active ingredients used in the treatment of a disease or disorder. This amount will achieve the goal of reducing or eliminating the said disease or disorder.
  • the term "therapeutically acceptable” refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) which are suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
  • patient means all mammals including humans. Examples of patients include humans, cows, dogs, cats, goats, sheep, pigs, and rabbits. Preferably, the patient is a human.
  • prodrug refers to a compound that is made more active in vivo.
  • Certain compounds disclosed herein may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley- VHCA, Zurich, Switzerland 2003).
  • Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the compound.
  • prodrugs can be converted to the compound by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.
  • Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
  • a wide variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug.
  • An example, without limitation, of a prodrug would be a compound which is administered as an ester (the "prodrug"), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.
  • the compounds disclosed herein can exist as therapeutically acceptable salts.
  • the present invention includes compounds listed above in the form of salts, including acid addition salts.
  • Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable.
  • Pharmaceutical Salts Properties, Selection, and Use (Stahl, P. Heinrich. Wiley- VCHA, Zurich, Switzerland, 2002).
  • terapéuticaally acceptable salt represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein.
  • the salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid.
  • Representative acid addition salts include acetate, adipate, alginate, L- ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylprop
  • basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
  • acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion.
  • the present invention contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.
  • Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • the cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1- ephenamine, and N.N-dibenzylethylenediamine.
  • nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine,
  • a salt of a compound can be made by reacting the appropriate compound in the form of the free base with the appropriate acid.
  • the compounds of the subject invention While it may be possible for the compounds of the subject invention to be administered as the raw chemical, it is also possible to present them as a pharmaceutical formulation. Accordingly, provided herein are pharmaceutical formulations which comprise one or more of certain compounds disclosed herein, or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvates thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art; e.g., in Remington's Pharmaceutical Sciences.
  • the pharmaceutical compositions disclosed herein may be manufactured in any manner known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
  • the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Typically, these methods include the step of bringing into association a compound of the subject invention or a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof ("active ingredient”) with the carrier which constitutes one or more accessory ingredients.
  • active ingredient a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Formulations of the compounds disclosed herein suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a nonaqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • compositions which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added.
  • Dragee cores are provided with suitable coatings.
  • concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately prior to use.
  • sterile liquid carrier for example, saline or sterile pyrogen-free water
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Formulations for parenteral administration include aqueous and nonaqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner.
  • Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.
  • the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
  • Certain compounds disclosed herein may be administered topically, that is by non-systemic administration. This includes the application of a compound disclosed herein externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
  • systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
  • Formulations suitable for topical administration include liquid or semi- liquid preparations suitable for penetration through the skin to the site of inflammation such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
  • the active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain embodiments, the active ingredient may comprise from 2% w/w to 5% w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the formulation.
  • Gels for topical or transdermal administration may comprise, generally, a mixture of volatile solvents, nonvolatile solvents, and water.
  • the volatile solvent component of the buffered solvent system may include lower (C1-C6) alkyl alcohols, lower alkyl glycols and lower glycol polymers.
  • the volatile solvent is ethanol.
  • the volatile solvent component is thought to act as a penetration enhancer, while also producing a cooling effect on the skin as it evaporates.
  • the nonvolatile solvent portion of the buffered solvent system is chosen from lower alkylene glycols and lower glycol polymers. In certain embodiments, propylene glycol is used.
  • the nonvolatile solvent slows the evaporation of the volatile solvent and reduces the vapor pressure of the buffered solvent system.
  • the amount of this nonvolatile solvent component, as with the volatile solvent, is determined by the pharmaceutical compound or drug being used. When too little of the nonvolatile solvent is in the system, the pharmaceutical compound may crystallize due to evaporation of volatile solvent, while an excess may result in a lack of bioavailability due to poor release of drug from solvent mixture.
  • the buffer component of the buffered solvent system may be chosen from any buffer commonly used in the art; in certain embodiments, water is used. A common ratio of ingredients is about 20% of the nonvolatile solvent, about 40% of the volatile solvent, and about 40% water. There are several optional ingredients which can be added to the topical composition.
  • Lotions include those suitable for application to the skin or eye.
  • An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.
  • Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
  • Creams, ointments or pastes are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely-divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy base.
  • the base may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap; a mucilage; an oil of natural origin such as almond, corn, arachis, castor or olive oil; wool fat or its derivatives or a fatty acid such as steric or oleic acid together with an alcohol such as propylene glycol or a macrogel.
  • the formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof.
  • suitable surface active agent such as an anionic, cationic or non-ionic surfactant such as a sorbitan ester or a polyoxyethylene derivative thereof.
  • Suspending agents such as natural gums, cellulose derivatives or inorganic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
  • Drops may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and, in certain embodiments, including a surface active agent.
  • the resulting solution may then be clarified by filtration, transferred to a suitable container which is then sealed and sterilized by autoclaving or maintaining at 98-100 0 C for half an hour.
  • the solution may be sterilized by filtration and transferred to the container by an aseptic technique.
  • bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%).
  • Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
  • Formulations for topical administration in the mouth include lozenges comprising the active ingredient in a flavored basis such as sucrose and acacia or tragacanth, and pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
  • lozenges comprising the active ingredient in a flavored basis such as sucrose and acacia or tragacanth
  • pastilles comprising the active ingredient in a basis such as gelatin and glycerin or sucrose and acacia.
  • compounds may be conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray. Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
  • Preferred unit dosage formulations are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.
  • compositions described above may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • Compounds may be administered orally or via injection at a dose of from 0.1 to 500 mg/kg per day.
  • the dose range for adult humans is generally from 5 mg to 2 g/day.
  • Tablets or other forms of presentation provided in discrete units may conveniently contain an amount of one or more compounds which is effective at such dosage or as a multiple of the same, for instance, units containing 5 mg to 500 mg, usually around 10 mg to 200 mg.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • the compounds can be administered in various modes, e.g. orally, topically, or by injection.
  • the precise amount of compound administered to a patient will be the responsibility of the attendant physician.
  • the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drug combination, the precise disorder being treated, and the severity of the indication or condition being treated.
  • the route of administration may vary depending on the condition and its severity.
  • the compounds described herein may be administered in combination with another therapeutic agent.
  • another therapeutic agent such as a pharmaceutically acceptable salt, ester, or prodrug thereof.
  • the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced).
  • the benefit of experienced by a patient may be increased by administering one of the compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
  • another therapeutic agent which also includes a therapeutic regimen
  • increased therapeutic benefit may result by also providing the patient with another therapeutic agent for diabetes.
  • the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.
  • Specific, non-limiting examples of possible combination therapies include use of certain compounds of the invention with agents found in the following pharmacotherapeutic classifications as indicated below.
  • combination regimens may include a variety of routes of administration and should include oral, intravenous, intraocular, subcutaneous, dermal, and inhaled topical.
  • compounds disclosed herein may be administered with an agent chosen from the group comprising: insulin, insulin derivatives and mimetics, insulin secretagogues, insulin sensitizers, biguanide agents, alpha-glucosidase inhibitors, insulinotropic sulfonylurea receptor ligands, meglitinides, protein tyrosine phosphatase-lB (PTP-IB) inhibitors, GSK3 (glycogen synthase kinase-3) inhibitors , GLP-I (glucagon like peptide-1), GLP-I analogs, DPP-IV (dipeptidyl peptidase IV) inhibitors, RXR ligands, sodium- dependent glucose co-transporter (SGLT2) inhibitors, glycogen phosphorylase A inhibitors, an AGE breaker, PPAR modulators, non-glitazone type PPAR ⁇ agonist, HMG-CoA reductase inhibitors, cholesterol-lowering agents, and others.
  • compounds disclosed herein may be administered with an agent chosen from the group comprising: insulin, metformin, Glipizide, glyburide, Amaryl, gliclazide, meglitinides, nateglinide, repaglinide, amylin mimetics (for example, pramlintide), PTP-112, SB-517955, SB-4195052, SB-216763, NN-57-05441, NN-57-05445, GW-0791, AGN- 19 4 20 4, T-1095, BAY R3401, acarbose, miglitol, voglibose, Exendin-4, DPP728, LAF237, vildagliptin , BMS477118, PT-100, GSK-823093, PSN-9301, T-6666, SYR-322, SYR-619, Liraglutide, CJC-1134-PC, naliglutide, MK
  • compounds disclosed herein may be administered with an agent chosen from the group comprising: cholescystokinin-A (CCK-A) agonists, serotonin and norepinephrine reuptake inhibitors (for example sibutramine), dopamine agonists (for example, bromocriptine and like) sympathomimetic agents, ⁇ 3 adrenergic receptor agonists, leptin, leptin analogues, leptin receptor agonists, galanin antagonists, lipase inhibitors (for example Orlistat), Neuropeptide-Y antagonists, glucocorticoid receptor agonists or antagonists, cannabinoid 1 receptor antagonists (for example, rimonabant and like), ciliary neurotropic factors (CNTF, for example Axokine), human agouti-related proteins (AGRP), ghrelin receptor antagonists, histamine 3 receptor antagonists, appetite suppressants (for example, bupro
  • CCK-A cholesc
  • compounds disclosed herein may be administered with an agent chosen from the group comprising: corticosteroids, non-steroidal anti-inflammatories, muscle relaxants and combinations thereof with other agents, anaesthetics and combinations thereof with other agents, expectorants and combinations thereof with other agents, antidepressants, anticonvulsants and combinations thereof; antihypertensives, opioids, topical cannabinoids, and other agents, such as capsaicin.
  • an agent chosen from the group comprising: corticosteroids, non-steroidal anti-inflammatories, muscle relaxants and combinations thereof with other agents, anaesthetics and combinations thereof with other agents, expectorants and combinations thereof with other agents, antidepressants, anticonvulsants and combinations thereof; antihypertensives, opioids, topical cannabinoids, and other agents, such as capsaicin.
  • compounds disclosed herein may be administered with an agent chosen from the group comprising: betamethasone dipropionate (augmented and nonaugemnted), betamethasone valerate, clobetasol propionate, prednisone, methyl prednisolone, diflorasone diacetate, halobetasol propionate, amcinonide, dexamethasone, dexosimethasone, fluocinolone acetononide, fluocinonide, halocinonide, clocortalone pivalate, dexosimetasone, flurandrenalide, salicylates, ibuprofen, ketoprofen, etodolac, diclofenac, meclofenamate sodium, naproxen, piroxicam, celecoxib, cyclobenzaprine, baclofen, cyclobenzaprine/lidocaine, baclof
  • the multiple therapeutic agents may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few minutes to four weeks.
  • certain embodiments provide methods for treating GPR119-mediated disorders in a human or animal subject in need of such treatment comprising administering to said subject an amount of a compound disclosed herein effective to reduce or prevent said disorder in the subject, in combination with at least one additional agent for the treatment of said disorder that is known in the art.
  • certain embodiments provide therapeutic compositions comprising at least one compound disclosed herein in combination with one or more additional agents for the treatment of GPRl 19 -mediated disorders.
  • diabetes type I and type II
  • conditions associated with diabetic diseases which include, but are not limited to, hyperglycemia, hyperlipidemia, hyperinsulinemia, insulin resistance, inadequate glucose tolerance, impaired glucose metabolism, diabetic nephropathy, glomerulosclerosis, diabetic neuropathy, erectile dysfunction, macular degeneration, diabetic retinopathy, chronic microvascular complications, peripheral vascular disease, cataracts, stroke, foot ulcerations, renal failure, kidney disease, ketosis, metabolic acidosis, and related disorders, obesity, myocardial infarction, angina pectoris, coronary artery disease, atherosclerosis, cardiac hypertrophy, allergic diseases, fatty liver disease, nonalcoholic steatohepatitis, liver fibrosis, kidney fibrosis, anorexia nervosa, bulimia vervosa, autoimmune diseases, inflammatory diseases including rheumatoid arthritis, asthma, chronic o
  • the disease is obesity and the effects to be achieved in a human or animal patient include decreasing body weight and controlling weight gain.
  • topical application of GPRl 19 agonists might be useful for the treatment of cellulite and other cosmetic conditions which are characterized by subcutaneous fat accumulation.
  • the disease is associated with perturbed bile acid metabolism, including, but not limited to gall bladder stones, cholecystitis, cholangitis, choledocholithiasis, jaundice, and obstetric cholestasis and the itch associated with it.
  • Metabolic diseases other than Type 1 and Type 2 diabetes which may be treated or prevented include, without limitation, metabolic syndrome and insulin resistance.
  • the compounds disclosed herein can be used to treat insulin resistance and other metabolic disorders such as atherosclerosis that are typically associated with an exaggerated inflammatory signaling.
  • the disease is a hyperproliferative condition of the human or animal body, including, but not limited to restenosis, inflammation, immune disorders, cardiac hypertrophy, atherosclerosis, pain, migraine, angiogenesis-related conditions or disorders, proliferation induced after medical conditions, including but not limited to surgery, angioplasty, or other conditions.
  • the compounds disclosed herein may be useful as anti-inflammatory agents with the additional benefit of having significantly less harmful side effects.
  • compositions may be used to treat arthritis, including but not limited to rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus, juvenile arthritis, acute rheumatic arthritis, enteropathic arthritis, neuropathic arthritis, psoriatic arthritis, and pyogenic arthritis.
  • the compositions may also be used in the treatment of pulmonary inflammation, such as that associated with viral infections and cystic fibrosis.
  • the particular inflammatory disease is rheumatoid arthritis.
  • Further inflammatory diseases which may be prevented or treated include, without limitation: asthma, allergies, respiratory distress syndrome or acute or chronic pancreatitis.
  • respiratory system diseases may be prevented or treated including but not limited to chronic obstructive pulmonary disease, pulmonary fibrosis, ulcerative colitis, inflammatory bowel disease, Crohn's disease, peptic ulceration, gastritis, psoriasis, and skin inflammation.
  • the disease to be treated by the methods provided herein may be an ophthalmologic disorder.
  • Ophthalmologic diseases and other diseases in which angiogenesis plays a role in pathogenesis may be treated or prevented and include, without limitation, dry eye (including Sjogren's syndrome), macular degeneration, closed and wide angle glaucoma, retinal ganglion degeneration, occular ischemia, retinitis, retinopathies, uveitis, ocular photophobia, and of inflammation and pain associated with acute injury to the eye tissue.
  • the ophthalmologic disease to be treated is glaucomatous retinopathy and/or diabetic retinopathy.
  • the ophthalmologic condition to be treated is post-operative inflammation or pain as from ophthalmic surgery such as cataract surgery and refractive surgery.
  • the disease to be treated by the methods provided herein may be an autoimmune disease.
  • Autoimmune diseases which may be prevented or treated include, but are not limited to: rheumatoid arthritis, inflammatory bowel disease, inflammatory pain, ulcerative colitis, Crohn's disease, periodontal disease, temporomandibular joint disease, multiple sclerosis, diabetes, glomerulonephritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, hemolytic anemia, autoimmune gastritis, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, atopic dermatitis, graft vs.
  • Inflammatory diseases which may be prevented or treated include, but are not limited to: asthma, allergies, respiratory distress syndrome or acute or chronic pancreatitis.
  • the particular autoimmune disease is rheumatoid arthritis.
  • the compounds provided herein are also useful in treating tissue damage in such diseases as vascular diseases, migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephritis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, periodontis, hypersensitivity, swelling occurring after injury, ischemias including myocardial ischemia, cardiovascular ischemia, and ischemia secondary to cardiac arrest, and the like. These compounds can also be used to treat allergic rhinitis, respiratory distress syndrome, endotoxic shock syndrome, and atherosclerosis.
  • the disease to be treated by the methods of the present invention may be a cardiovascular condition.
  • said cardiovascular condition is chosen from atherosclerosis, cardiac hypertrophy, idiopathic cardiomyopathies, heart failure, angiogenesis-related conditions or disorders, and proliferation induced after medical conditions, including, but not limited to restenosis resulting from surgery and angioplasty.
  • the disease to be prevented or treated by the methods of the present invention may be autism.
  • GIP glucose -dependent insulinotropic polypeptide
  • GPRl 19 agonists increase GLP-I and GIP secretion both in vitro and in vivo
  • GPRl 19 agonists in this patent might be important for the prevention or treatment of bone loss induced by age or diseases in which the normal functions of osteobalsts or osteoclasts are altered.
  • Such diseases include, for example, osteopenia and osteoporosis.
  • Reagents a) 2-bromo-l,l-diethoxyethane, IPA, reflux; b) NBS, rt; c) NaH, Ar 102 NH 2 , NMP; d) tert-butyl 4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-5,6-dihydropyridine-l(2H)-carboxylate, Pd(PPh 3 ) 2 Cl 2 , K 2 CO 3 e) TFA, DCM. f) DIPEA, DCM g) Ar 103 -X, Cs 2 CO 3 , NMP, microwave, 150 0 C. h) Pd/C, H 2 .
  • Scheme 2 Scheme 2
  • Reagents a) Ar 103 -X, DIPEA, DMF, 100 0 C, 2 h; b)LiOH, THF:H 2 O (6:1), 60 0 C, 16 h; c)HATU, DIPEA, rt, 1 h; d) POCl 3 , reflux, 45 min; e) NaH, DMF, rt, 15 min.
  • Step 4 tert-Butyl 4-(8-(2-fluoro-4-(methylsulfonyl)phenylamino)imidazo[l,2- a]pyrazin-3-yl)-5,6-dihydropyridine-l(2H)-carboxylate
  • Step 4 8-Chloro-3-(l-(5-ethylpyrimidin-2-yl)piperidin-4-yl)-[l,2,4]triazolo[4,3- ajpyrazine
  • TThhee ttiittllee ⁇ c ;oommppcound was synthesized as described for EXAMPLE 3 using N-(2-methyl-6-(methylsulfonyl)pyridin-3-yl)-3-(l,2,3,6-tetrahydropyridin-4- yl)imidazo[l,2-a]pyrazin-8-amine and 2-chloro-5-fluoropyrimidine as the starting materials.
  • Step 2 l-(5-Ethylpyrimidin-2-yl)piperidine-4-carboxylic acid
  • Step 5 N'-(5-Bromopyrimidin-4-yl)-l-(5-ethylpyrimidin-2-yl)piperidine-4- carbohydrazide
  • Step 6 8-Bromo-3-(l-(5-ethylpyrimidin-2-yl)piperidin-4-yl)-[l,2,4]triazolo[4,3- cjpyrimidine
  • Step 7 3-(l-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)-N-(2-fluoro-4-(methylsulfonyl) phenyl)-[l,2,4]triazolo[4,3-c]pyrimidin-8-amine
  • Step 1 4-Bromo-6-chloropyridazin-3 -amine
  • Step 3 6-chloro-N-(2-fluoro-4-(methylsulfonyl)phenyl)imidazo[l,2-b]pyridazin-8- amine flask was placed a solution of 2-fluoro-4- (methylsulfonyl) benzenamine (8.8 g, 46.56 mmol, 1.20 equiv) in tetrahydrofuran (200 mL), potassium butan-1-olate (10.9 g, 97.32 mmol, 2.50 equiv), 8-bromo-6- chloroimidazo [1,2-b] pyridazine (9 g, 38.96 mmol, 1.00 equiv).
  • Step 4 N-(2-Fluoro-4-(methylsulfonyl)phenyl)imidazo[l,2-b]pyridazin-8-amine
  • Step 5 3-Bromo-N-(2-fluoro-4-(methylsulfonyl)phenyl)imidazo[l,2-b]pyridazin-8- amine
  • Step 6 Tert-butyl 4-(8-(2-fluoro-4-(methylsulfonyl)phenylamino)imidazo[l ,2- b]pyridazin-3-yl)-5,6-dihydropyridine-l(2H)-carboxylate
  • Step 1 N-(2-Fluoro-4-(methylsulfonyl)phenyl)-3-(l,2,3,6-tetrahydropyridin-4- yl)imidazo[l,2-b]pyridazin-8-amine
  • Step_l 3-(l-(5-Ethylpyrimidin-2-yl)-l,2,3,6-tetrahydropyridin-4-yl)-N-(2-fluoro-4- (methylsulfonyl)phenyl)imidazo[ 1 ,2-b]pyridazin-8-amine
  • Step 1 Tert-butyl 4-(3-bromoimidazo[l,2-a]pyrazin-8-yl)piperazine-l-carboxylate
  • Step 2 Tert-butyl 4-(3-(2-fluoro-4-(methylsulfonyl)phenylamino)imidazo[l ,2- a]pyrazin-8-yl)piperazine-l-carboxylate
  • Step 2 8-Bromo-3-(l-(5-ethylpyrimidin-2-yl)piperidin-4-yl)imidazo[l,2- a]pyridine
  • Step 3 3-(l-(5-Ethylpyrimidin-2-yl)piperidin-4-yl)-N-(2-methyl-6- (methylsulfonyl) pyridin-3-yl)imidazo[l,2-a]pyridin-8-amine
  • Step 1 Tert-butyl 4-(l-bromo-2-oxoethyl)piperidine-l-carboxylate
  • Step 3 Tert-butyl 4-(8-bromo-6-chloroimidazo[l,2-b]pyridazin-3-yl)piperidine-l- carboxylate
  • Step 4 Tert-butyl 4-(6-chloro-8-(2-methyl-6-(methylsulfonyl)pyridin-3- ylamino)imidazo[l,2-b]pyridazin-3-yl)piperidine-l-carboxylate
  • Step 5 Tert-butyl 4-(8-(2-methyl-6-(methylsulfonyl)pyridin-3- ylamino)imidazo[l,2-b]pyridazin-3-yl)piperidine-l-carboxylate
  • Step 1 3,6-Dichloro-N-(2-methyl-6-(methylsulfonyl)pyridin-3-yl)pyridazin-4- amine
  • Step 2 6-Chloro-3-(l-(5-ethylpyrimidin-2-yl)piperidin-4-yl)-N-(2-methyl-6- (methylsulfonyl)pyridin-3-yl)-[l,2,4]triazolo[4,3-b]pyridazin-8-amine
  • Step 3 3-(l-(5-ethylpyrimidin-2-yl)piperidin-4-yl)-N-(2-methyl-6- (methylsulfonyl) pyridin-3-yl)-[l,2,4]triazolo[4,3-b]pyridazin-8-amine
  • SMILES Simplified Molecular Input Line Entry System
  • SMILES is a modern chemical notation system, developed by David Weininger and Daylight Chemical Information Systems, Inc., that is built into all major commercial chemical structure drawing software packages. Software is not needed to interpret SMILES text strings, and an explanation of how to translate SMILES into structures can be found in Weininger, D., /. Chem. Inf. Comput. ScL 1988, 28, 31-36. All SMILES strings used herein, as well as many IUPAC names, were generated using CambridgeSoft's ChemDraw 10.0 or 11.0.

Abstract

L'invention concerne des composés, et leurs procédés d'utilisation, pouvant être utiles comme inhibiteurs du GPRl 19 pour traiter ou prévenir des maladies, notamment des maladies cardio-vasculaires et métaboliques.
PCT/US2010/022588 2009-01-31 2010-01-29 Modulateurs hétérocycliques du gpr119 pour le traitement de maladies WO2010088518A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14895609P 2009-01-31 2009-01-31
US61/148,956 2009-01-31

Publications (2)

Publication Number Publication Date
WO2010088518A2 true WO2010088518A2 (fr) 2010-08-05
WO2010088518A3 WO2010088518A3 (fr) 2011-01-27

Family

ID=42396367

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/022588 WO2010088518A2 (fr) 2009-01-31 2010-01-29 Modulateurs hétérocycliques du gpr119 pour le traitement de maladies

Country Status (1)

Country Link
WO (1) WO2010088518A2 (fr)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113947A1 (fr) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
WO2012086735A1 (fr) * 2010-12-22 2012-06-28 大正製薬株式会社 Composé hétérocyclique condensé
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2014011926A1 (fr) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique
JP2014509600A (ja) * 2011-03-14 2014-04-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド
US8716282B2 (en) 2009-10-30 2014-05-06 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
WO2014082230A1 (fr) * 2012-11-28 2014-06-05 上海希迈医药科技有限公司 Dérivés de pyrrolo-triazine, leur procédé de préparation et leur application médicale
US8859543B2 (en) 2010-03-09 2014-10-14 Janssen Pharmaceutica Nv Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
CN104725323A (zh) * 2014-10-16 2015-06-24 江苏华益科技有限公司 一种2-甲氧基-4-肼基-5-氟嘧啶的合成工艺
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
JP2015525752A (ja) * 2012-07-13 2015-09-07 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性の調節物質としてのイミダゾピラジン誘導体
WO2015166370A1 (fr) 2014-04-28 2015-11-05 Pfizer Inc. Composés hétéroaromatiques et leur utilisation en tant que ligands de la dopamine d1
US9255100B2 (en) 2010-09-10 2016-02-09 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
US9290500B2 (en) 2012-02-17 2016-03-22 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
US9458108B2 (en) 2006-08-08 2016-10-04 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
US9550784B2 (en) 2012-07-09 2017-01-24 Beerse Pharmaceutica NV Inhibitors of phosphodiesterase 10 enzyme
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
US9683003B2 (en) 2014-07-01 2017-06-20 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
US9695154B2 (en) 2013-07-02 2017-07-04 Millennium Pharmaceuticals, Inc. Heteroaryl inhibitors of sumo activating enzyme
CN109053693A (zh) * 2018-09-20 2018-12-21 周银平 哒嗪胺类化合物的制备及其应用
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10472363B2 (en) 2016-09-02 2019-11-12 Cyclerion Therapeutics, Inc. SGC stimulators
CN110563723A (zh) * 2019-07-23 2019-12-13 上海药明康德新药开发有限公司 一种6-溴-3-(哌啶-4-基)咪唑并[1,2-a]吡啶的制备方法
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
US10975056B2 (en) 2016-06-13 2021-04-13 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of DNMT1
US11053195B2 (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US11110055B2 (en) 2014-12-18 2021-09-07 Genzyme Corporation Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors
CN114072408A (zh) * 2019-07-08 2022-02-18 南京明德新药研发有限公司 作为porcupine抑制剂的化合物及其应用
WO2023016567A1 (fr) * 2021-08-13 2023-02-16 Ascentage Pharma (Suzhou) Co., Ltd. Méthodes de traitement d'une maladie ou d'un trouble

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120702A2 (fr) * 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Agonistes du récepteur de gpr119 dans des procédés d'augmentation de la masse osseuse et de traitement de l'ostéoporose et autres états se caractérisant par une masse osseuse faible, et thérapie de combinaison associée
WO2008008895A1 (fr) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Agonistes gpr119 destinés au traitement du diabète et des troubles associés
US20080058339A1 (en) * 2006-08-30 2008-03-06 Biovitrum New compounds
WO2008137435A1 (fr) * 2007-05-04 2008-11-13 Bristol-Myers Squibb Company Agonistes [6,6] and [6,7]-bicycliques du récepteur gpr 119 couplé à la protéine g
US20090018055A1 (en) * 2007-05-04 2009-01-15 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007120702A2 (fr) * 2006-04-11 2007-10-25 Arena Pharmaceuticals, Inc. Agonistes du récepteur de gpr119 dans des procédés d'augmentation de la masse osseuse et de traitement de l'ostéoporose et autres états se caractérisant par une masse osseuse faible, et thérapie de combinaison associée
WO2008008895A1 (fr) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Agonistes gpr119 destinés au traitement du diabète et des troubles associés
US20080058339A1 (en) * 2006-08-30 2008-03-06 Biovitrum New compounds
WO2008137435A1 (fr) * 2007-05-04 2008-11-13 Bristol-Myers Squibb Company Agonistes [6,6] and [6,7]-bicycliques du récepteur gpr 119 couplé à la protéine g
US20090018055A1 (en) * 2007-05-04 2009-01-15 Bristol-Myers Squibb Company [6,5]-bicyclic gpr119 g protein-coupled receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEMPLE, G. ET AL.: 'Discovery of the First Potent and Orally Efficacious Agonist of the Orphan G-Protein Coupled Receptor 119' JOURNAL OF MEDICINAL CHEMISTRY vol. 51, no. 17, 2008, pages 5172 - 5175 *

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9718788B2 (en) 2006-08-08 2017-08-01 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
US9458108B2 (en) 2006-08-08 2016-10-04 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8716282B2 (en) 2009-10-30 2014-05-06 Janssen Pharmaceutica Nv Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
US8859543B2 (en) 2010-03-09 2014-10-14 Janssen Pharmaceutica Nv Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
WO2011113947A1 (fr) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combinaisons d'agonistes de gpr119 et d'inhibiteurs de dpp-iv, linagliptine, pour le traitement du diabète et d'états apparentés
US9255100B2 (en) 2010-09-10 2016-02-09 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
WO2012086735A1 (fr) * 2010-12-22 2012-06-28 大正製薬株式会社 Composé hétérocyclique condensé
JP2014509600A (ja) * 2011-03-14 2014-04-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド
US10604523B2 (en) 2011-06-27 2020-03-31 Janssen Pharmaceutica Nv 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
US9290500B2 (en) 2012-02-17 2016-03-22 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
US10202389B2 (en) 2012-02-17 2019-02-12 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
US9796725B2 (en) 2012-02-17 2017-10-24 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
US9663525B2 (en) 2012-02-17 2017-05-30 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
US9669035B2 (en) 2012-06-26 2017-06-06 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders
US9550784B2 (en) 2012-07-09 2017-01-24 Beerse Pharmaceutica NV Inhibitors of phosphodiesterase 10 enzyme
WO2014011926A1 (fr) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique
JP2015525752A (ja) * 2012-07-13 2015-09-07 ユーシービー バイオファルマ エスピーアールエル Ｔｎｆ活性の調節物質としてのイミダゾピラジン誘導体
WO2014082230A1 (fr) * 2012-11-28 2014-06-05 上海希迈医药科技有限公司 Dérivés de pyrrolo-triazine, leur procédé de préparation et leur application médicale
US11053195B2 (en) 2013-03-15 2021-07-06 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9695154B2 (en) 2013-07-02 2017-07-04 Millennium Pharmaceuticals, Inc. Heteroaryl inhibitors of sumo activating enzyme
US10450269B1 (en) 2013-11-18 2019-10-22 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9174986B2 (en) 2013-12-10 2015-11-03 Genzyme Corporation Tropomyosin-related kinase (Trk) inhibitors
US10166239B2 (en) 2013-12-10 2019-01-01 Genzyme Corporation Tropomyosin-related kinase (Trk) inhibitors
US9611265B2 (en) 2013-12-10 2017-04-04 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
US11878024B2 (en) 2013-12-10 2024-01-23 Genzyme Corporation Tropomyosin-related kinase (Trk) inhibitors
US11406644B2 (en) 2013-12-10 2022-08-09 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
US20170037049A1 (en) * 2014-04-28 2017-02-09 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
WO2015166370A1 (fr) 2014-04-28 2015-11-05 Pfizer Inc. Composés hétéroaromatiques et leur utilisation en tant que ligands de la dopamine d1
US9856263B2 (en) 2014-04-28 2018-01-02 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
US10335410B2 (en) 2014-07-01 2019-07-02 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
US9962386B2 (en) 2014-07-01 2018-05-08 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
US10780090B2 (en) 2014-07-01 2020-09-22 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
US9683003B2 (en) 2014-07-01 2017-06-20 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
CN104725323A (zh) * 2014-10-16 2015-06-24 江苏华益科技有限公司 一种2-甲氧基-4-肼基-5-氟嘧啶的合成工艺
US11793749B2 (en) 2014-12-18 2023-10-24 Genzyme Corporation Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors
US11110055B2 (en) 2014-12-18 2021-09-07 Genzyme Corporation Pharmaceutical formulations of tropomyosin related kinase (TRK) inhibitors
US10975056B2 (en) 2016-06-13 2021-04-13 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of DNMT1
US10858363B2 (en) 2016-09-02 2020-12-08 Cyclerion Therapeutics, Inc. SGC stimulators
US11731977B2 (en) 2016-09-02 2023-08-22 Cyclerion Therapeutics, Inc. SGC stimulators
US10472363B2 (en) 2016-09-02 2019-11-12 Cyclerion Therapeutics, Inc. SGC stimulators
CN109053693A (zh) * 2018-09-20 2018-12-21 周银平 哒嗪胺类化合物的制备及其应用
CN114072408A (zh) * 2019-07-08 2022-02-18 南京明德新药研发有限公司 作为porcupine抑制剂的化合物及其应用
CN114072408B (zh) * 2019-07-08 2023-05-12 南京明德新药研发有限公司 作为porcupine抑制剂的化合物及其应用
CN110563723A (zh) * 2019-07-23 2019-12-13 上海药明康德新药开发有限公司 一种6-溴-3-(哌啶-4-基)咪唑并[1,2-a]吡啶的制备方法
WO2023016567A1 (fr) * 2021-08-13 2023-02-16 Ascentage Pharma (Suzhou) Co., Ltd. Méthodes de traitement d'une maladie ou d'un trouble

Also Published As

Publication number Publication date
WO2010088518A3 (fr) 2011-01-27

Similar Documents

Publication Publication Date Title
WO2010088518A2 (fr) Modulateurs hétérocycliques du gpr119 pour le traitement de maladies
EP3463343B1 (fr) Inhibiteurs hétérocycliques de ptpn11
US20090105124A1 (en) Heterocyclic modulators of tgr5
EP2545058B1 (fr) COMPOSÉS DE TETRAZOLO[1,5-a]PYRAZINE COMME INHIBITEURS DE RÉCEPTEURS DE L'HISTAMINE
US20090054304A1 (en) Heterocyclic modulators of tgr5 for treatment of disease
WO2010048149A2 (fr) Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
AU2013334236B2 (en) Heteroaryl inhibitors of PDE4
AU2017371084B2 (en) Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
US20080221161A1 (en) Heterocyclic modulators of tgr5 for treatment of disease
WO2008067222A1 (fr) Modulateurs hétérocycliques de tgr5
US20090035306A1 (en) Quinazolinone modulators of tgr5
JP7387627B2 (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
WO2008011560A2 (fr) Inhibiteurs de la rho kinase à base de benzothiophène
US8080566B1 (en) Carbazole inhibitors of histamine receptors for the treatment of disease
WO2010016846A1 (fr) Modulateurs hétérocycliques de tgr5 pour le traitement d'une maladie
WO2016004417A1 (fr) Inhibiteurs de la gls1 pour le traitement de maladies
WO2021081074A1 (fr) Inhibiteurs bicyclo[1.1.1]pentane de la double fermeture à glissière de leucine kinase (dlk) destinés au traitement de maladie
US20160002248A1 (en) Gls1 inhibitors for treating disease
WO2014066743A1 (fr) Composés hétérocycliques pour l'inhibition de pask
EP3630116A2 (fr) Inhibiteurs de la kinase atr à base de tétrahydropyrido[4,3-d]pyrimidine
WO2010014739A2 (fr) Modulateurs hétérocycliques du tgr5

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10736477

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10736477

Country of ref document: EP

Kind code of ref document: A2